Theranexus

Report Publication Announcement • Dec 21, 2022

THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2023

Lyon, France – 21 December 2022 – 6:00pm CET - Theranexus, an innovative biopharmaceutical company innovating in the treatment of rare neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its financial communication agenda for 2023. Each publication will be released after Euronext market closing, unless otherwise specified. These dates are given as an indication, they are likely to be modified if necessary.

Indicative calendar

Events	Dates
December 31th 2022 Cash position as at	18 January 2023
	(before stock exchange)
2022 Year-End Results and Cash position as at March 31th 2023	12 April 2023
Cash position as at June 30th 2023	11 July 2023
2023 Half-Year Results	28 September 2023
Cash position as at September 30th 2022	17 October 2023

About Theranexus

Theranexus is an innovative biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.

The company has a unique platform for the identification and characterization of advanced therapy drug candidates targeting rare neurological disorders and an initial drug candidate in clinical development for Batten disease. Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

More information at http://www.theranexus.com Click and follow us on Twitter and Linkedln

Contacts

THERANEXUS Thierry Lambert Chief Financial Officer contact@theranexus.com

NEWCAP Théo Martin/Pierre Laurent Investor Relations +33 (0)1 44 71 94 97 theranexus@newcap.eu

FP2COM Florence Portejoie Media Relations + 33 (0)6 07 76 82 83 fportejoie@fp2com.fr